Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In 2022, 1236 new clinical studies were initiated, globally, testing PD-1/PD-L1 targeted immune checkpoint inhibitors in cancer, a 54% increase from 2017.
There are >3000 ongoing clinical studies, worldwide, testing PD-1/PD-L1 inhibitors; > 80% of these trials are evaluating these agents in combination. The combination agents target > 300 different pathways.
ICI therapies are effective only in a small subset of patients and show limited therapeutic potential due to their inability to demonstrate efficacy in ‘cold’ or unresponsive tumor microenvironments (TMEs)
…